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Xydas et al Perioperative Managementcan likely apply to most cardiac surgery programs at or
above national transfusion rates.Study Limitations
The limitations of this study include those inherent to
nonrandomized trials using historical control groups. There
were minor baseline differences between our patient
groups. These changes include small differences in patient
age, New York Heart Association class, and rates of hyper-
tension and hypercholesterolemia. Group II was therefore
a slightly older and sicker cohort of patients who may rep-
resent slight changes in referral patterns in our clinical prac-
tice over time. Given these small differences, group II may
be expected to have a slightly higher inherent risk of trans-
fusion than group I. In addition, the sustained decreases in
blood and component transfusion suggest that these de-
creases are attributable to our blood conservation initiative.
This study was not designed to include patients who are tra-
ditionally at higher risk for bleeding, such as those having
ventricular assist device implantation or thoracic aortic sur-
gery. Outcome analysis was limited to early mortality and
morbidity, and more extensive study is needed that evalu-
ates the effects of a blood conservation strategy on long-
term patient outcomes.
Although an integrated blood conservation initiative led
to broad adoption at Morristown Medical Center, blood
transfusion thresholds did, in some instances, vary in the
postoperative period on the basis of clinical judgment.
Last, the data reported do not include an analysis of cost.
Real cost-savings should be evaluated in a more extensive
study that includes not only the savings associated with de-
creased transfusion but also the cost of implementation of
a blood conservation protocol (eg, use of cell salvage, staff
education, and point-of-care testing).P
MCONCLUSIONS
Systematic implementation of a comprehensive blood
conservation algorithm can be rapidly introduced in a com-
munity-based cardiac surgery program, leading to signifi-
cant reductions in blood and blood component use and
with no measurable effect on early patient mortality and
morbidity. Point-of-care testing can successfully direct
blood component transfusion in patients with coagulopathy.
Further research will determine the effects of reduced trans-
fusions on long-term outcomes of patients undergoing car-
diac surgery.
The authors thank Patricia A. Gortych and team for meticulous
data collection and database management. Our cardiac research
team was integral to the institutional review board protocol prep-
aration and submission. The cardiac post-recovery unit and floor
nurses were pivotal in the formulation and adoption of the blood
conservation program; without them, this study would not have
been possible.The Journal of Thoracic and CaReferences
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Dr James Maxwell (Missoula, Mont). Allogeneic blood trans-
fusion has been under intense review for the last decade, and
a 2006 review inCirculation referred to post-cardiac surgery trans-
fusions as a silent epidemic. Significant evidence of the harmful
effects of transfusion have accumulated to the point where the cur-
rent search is for meaningful evidence to support transfusion ab-
sent life-threatening hemorrhage. Still, the frequency ofrdiovascular Surgery c Volume 143, Number 4 933
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Mtransfusion after cardiac surgery in the United States varies widely
from 0% to 75%. It is in this context that the authors implemented
a comprehensive blood conservation program in a community hos-
pital. The study is actually a retrospective comparison of historical
controls versus transfusion rates after coronary artery bypass graft-
ing, valve, and combined cases. The statistical analysis suggested
a reduction in transfusion of FFP, red blood cells, and cryoprecipi-
tate. Despite stopping aspirin for 10 days preoperatively, a reduc-
tion in platelet transfusion was not noted. For reasons unclear,
excluded from analysis from both groups were outliers requiring
more than 10 units of blood, although the statistical impact of
this was nil. A 41% reduction in blood transfusion was achieved
over the study period and persisted for the 3 months after the study
interval. The post-study transfusion rate was approximately 50%
for the combined group. There were no differences in major mor-
bidity between the groups. Despite improvements in transfusion
rates, no reductions in prespecified morbidity were noted. I also
note the overall excellent results of your group across the board
for surgical outcomes, which may explain why there was no im-
provement in surgical outcomes despite improvements in blood
use.
I have thousands of questions actually because this is a great
topic, but I will limit my questions to 3.
Did you follow preoperative and discharge hemoglobin levels?
If so, what were the discharge hemoglobin levels?
You mentioned intraoperative cerebral oximetry in your article,
although not in the presentation this morning. Do you have an in-
traoperative transfusion trigger based on intraoperative measure-
ments of cerebral oximetry?
Given that there was no difference in platelet transfusions, do
you still exclude aspirin for 10 days preoperatively in patients
with coronary disease given the known positive impact of aspirin
in the coronary artery bypass grafting group?
Dr Xydas. In terms of the comment about the outliers, it was
our statistical consultants who thought that cases with more than
10 red blood cells should be excluded. We ran the analysis with
or without these exclusions, and the results were the same, al-
though overall average numbers of transfusions were obviously
higher where we did not exclude those numbers, but the relative
reductions were the same with both analyses.
In terms of hemoglobin, we did track that in the 2 patient
groups. The baseline hemoglobin was no different between the
groups. The nadir hemoglobin, which was interesting to us, was
no different. It was 8.8 for both patient groups. The last hemoglo-
bin before the patient going home was slightly different. It was
a statistical difference. It decreased to 9.7 from 10.0 between group
II and group I. The conclusions we drew were that most of the re-
ductions in blood we sawmay have been more a result of the blood
conservation portions as opposed to the changes in thresholds of
hemoglobin with time, although likely it was both factors that
were involved, though the overall differences in the post-hemoglo-
bin even before discharge were small but different.
In terms of cerebral oximetry, our threshold for hemoglobin in
routine cases for transfusion was 6.0 on pump. We use cerebral
oximetry and carotid studies preoperatively to guide individual pa-
tient decisions. If there were cases of cerebrovascular disease that
was significant on carotid studies or a decrease in the baseline ce-
rebral oximetry on pump into the red zone, we did initially just934 The Journal of Thoracic and Cardiovascular Surgchange pH management to try to fix this. If they were still in the
red so to speak in terms of the changewith time as opposed to base-
line cerebral oximetry, we increased the hemoglobin threshold
from to 7 from 6. This was a decision we made intraoperatively.
In terms of the postoperative stroke incidence, it was no differ-
ent at 30 days between the patient groups, so it seemed at least in
the early postoperative mortality and morbidity to be safe in terms
of lowering these hemoglobin thresholds.
In terms of not seeing improvements in outcomes over time, this
was approximately 500 patients (group I vs II), and we only looked
through 30 days, so likely we would have needed higher patient
numbers to be statistically powered to see any small improvements
in terms of our initiatives with time. Certainly future studies with
longer term outcomes are going to address these questions.
DrRichard Shemin (Los Angeles, Calif). As you know, the So-
ciety of Thoracic Surgeons’ workforce on evidence-based surgery
has an excellent guidelines manuscript that is being reviewed and
another version coming out on the various blood conservation
strategies that I think we could all use.
How many of your patients came to the operating room so ane-
mic that they required a blood transfusion despite a low prime vol-
ume? Often, when we institute these blood conservation strategies,
we can see an immediate impact, but sustaining it over time is of-
ten a challenge because people lapse back into old habits? Have
you continued your task force? Do you continue to monitor to
maintain your good results?
Dr Xydas. The algorithms recently published were the impetus
and laid the groundwork for much of our program, and that was
overall helpful to have on a national front in terms of an impetus
for this kind of program.
In terms of the on-pump transfusion rates, they were approxi-
mately 35% and slightly lower in group II as opposed to group I in-
traoperatively. Postoperatively there was still a fair amount of
blood given in the postoperative period. I mentioned the differ-
ences in the hemoglobins. There were no differences in the nadir
but differences that were small in terms of the postdischarge hemo-
globin. We did tend to see relatively late transfusions, which
thwarted a lot of our effort, and so itwas really amatter of a 3-month
period of trying to bring home this message to everyone involved
(pulmonologists, cardiologists, intensive care unit, nurses) and of
quarterly analysis that are key. We did not see a decline in benefits
that we saw in the 3-month follow-up period, but certainly there is
going to still be that inertia to go back to the old method, so it is
going to be important to continue bringing that message home
with time and continuing with the task force, which are our plans.
I mentioned it was a 40% overall decrease in blood transfusion
rates. We were most effective in reducing cryoprecipitate and FFP
administration as opposed to blood, likely for those reasons in
terms of anyone being able to give blood even where we had the
strategy employed. In the future, wemaymake it mandatory to dis-
cuss with the surgeon or to okay an order for blood before going
forward. We just wanted to do this gently to make this palatable
for everybody, but certainly the easy one was the FFP and the cry-
oprecipitate, namely, for cryotherapy our rates of transfusion de-
creased by 67% with the point-of-care testing versus
coagulopathic patients receiving transfusions of FFP and platelets.
Platelets primarily were necessary on postoperative point-of-care
testing.ery c April 2012
Xydas et al Perioperative ManagementI know there was a question about the aspirin. We stop that rou-
tinely for isolated valve cases without coronary disease. It did not
seem tomake a difference, and that was really just the effects of the
pump on platelet function with time more so than the effects of the
aspirin perioperatively.
Dr Danny Chu (Houston, Tex). This is a great program. I con-
gratulate you for doing this. Have you seen any barriers in adopting
this program? If so, what are your suggestions for overcoming
those barriers in terms of having surgeons not adopting these
guidelines and what not?
Dr Xydas. The first buy-in has to be with the surgeons. In our
program there are only 4, and it really led by us wanting to do
this that helped bring the message home. To us, that was the easiestThe Journal of Thoracic and Capart of it, to see the data and guidelines in terms of their change,
and having this buy-in and making it something we would cham-
pion with time. We had multiple grand rounds with the cardiolo-
gists. That was where it really took more time. There are
always, ‘‘Well, this guy is going to have ischemic optic neuritis,
I’ve seen it 20 years ago, wemust give blood,’’ those sort of discus-
sions, which are not evidenced-based and just a matter of being dil-
igent and absolutely ongoing in terms of the efforts of education
with time. That is where it takes an effort longitudinally because
there is a tendency to have a decrease that is immediate that makes
you feel good but certainly a tendency to go back up with inertia of
the old habits, so that is where I think a lot of the bulk of the effort
has to be long term.rdiovascular Surgery c Volume 143, Number 4 935
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